( LAGUNA NIGUEL Calif.--(BUSINESS WIRE)-...)Aeolus Pharmaceuticals' AEOL 10113 May Play an Important Role,Regulating the Oxidative Damage Induced by Ionizing Radiation,Health

LAGUNA NIGUEL, Calif.--(BUSINESS WIRE)--Apr 23, 2007 - Aeolus Pharmaceuticals, Inc. (OTCBB:AOLS) announced the presentation of data by researchers at Loma Linda University Medical Center showing that one of the Company's metalloporphyrin antioxidants, AEOL 10113, may play an important role regulating the oxidative damage induced by ionizing radiation.

Radiation therapy is used alone or in combination with surgery and chemotherapy in the care and management of nearly all adult and approximately 75% of pediatric patients with central nervous system malignancies. Success in controlling a brain cancer by radiation therapy hinges on being able to inactivate the cancer cells while preserving normal tissue function.

This study evaluated retinal endothelial cell response to radiation in the presence of a metalloporphyrin antioxidant, AEOL 10113, using monkey choroid-retina endothelial cells. AEOL 10113 was added to the cells one hour prior to the administration of a single, 10 grey dose of radiation. Statistically significant (P less than 0.05), dose-dependent protection of normal retinal endothelial cells by AEOL 10113 was seen at 24 hours and 48 hours following irradiation. In addition, cell viability was significantly enhanced at 24 hours and 48 hours in non-irradiated endothelial cells cultured with AEOL 10113 at 10ug (P less than 0.05). Laser scanning cytometry showed AEOL 10113 altered cell cycle kinetics and led to significantly (p less than 0.05) increased G1 population 48 hours following irradiation.

The Potential for Metalloporphyrin Antioxidants in Radiotherapy for Cancer

Radiotherapy treatment in cancer has the positive effect of tumor destruction, but also has the negative effect of normal tissue damage. Optimal dosing in radiotherapy balances maximum tumor destruction with minimal toxicity and damage to normal tissue. The "ionizing radiation" used in cancer radiotherapy generates reac
'"/>

Page: 1 2 3
Related medicine technology :

1. Study Demonstrating Aeolus Compounds Neuroprotection in Parkinsons Disease Published in the Journal of Neuroscience
2. Aeolus Pharmaceuticals AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy
3. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
4. Aeolus Pharmaceuticals Announces Successful Completion of Multiple Dose Safety Study of AEOL 10150
5. Faust Pharmaceuticals Phase IIa Results for Parkinsons Disease Presented at International Congress of Parkinsons Disease and Movement Disorders
6. Data from Rexahn Pharmaceuticals Phase I Trial of RX-0201 (Archexin) to Be Presented at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago
7. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
8. ACADIA Pharmaceuticals Schizophrenia Programs to Be Presented at the 2007 International Congress on Schizophrenia Research
9. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
10. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
11. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis